Table 2

Outcomes in the studies included in the meta-analysis
First Author [Reference No.] Outcomes, n° (%) of patients in Peg-IFN α-2a/α-2b group
RVR EVR ETR SVR Discontinuation of therapy for adverse events in patients with genotype 1 all genotypes Peg-IFN reduction for adverse events in patients with all genotypes
Yenice [16] # 28(75.7)/27(73) 18(48.6)/13(35.1) 3 (7.5)/3 (7.5) 3 (7.5)/3 (7.5)
Di Bisceglie [17] § 14(7.4)/22(11.5) 74(39.1)/84(43.9)
Escudero [18] † 15(25.4)/10(17.2) 33(55.9)/29(50) 12(20.3)/7(12.1) 30(50.8)/27(46.6) 12(13.1)/10(10.8) 8(8.7)/7(7.6)
McHutchison [19] $ 123(11.9)/116(11.4) 466(45)/407(39.9) 667(64.4)/542(53.2) 423(40.9)/406(39.8) 135(13)/129(12.6) 135(13)/129(12.6) 264(25.5)/254(24.9)
Ascione [20] § 51(54.8)/37(39.8) 3 (3.2)/13 (14) 4(2.5)/22(13.7)
Lee [21] ^ 16(76.2)/12(75) 16(76.2)/13(81.3) 8(38)/10(62.5) 8(10.1)/5(10.6)
Rumi [22] ç 34(37)/26(30) 60(66)/40(46) 59(65)/38(44) 44(48)/28(32) 16(7.5)/17(7.7) 22(10.3)/14(6.3)

Dosage of ribavirin

# 4064 kg of weight: 800 mg/day; 65–85 kg: 1,000 mg/day; >85 kg: 1,200 mg/day.

§ <75 kg of weight: 1,000 mg/day; ≥75 kg: 1,200 mg/day.

† ≤65 kg of weight: 800 mg/day; 65–75 kg: 1,000 mg/day; >75 kg: 1,200 mg/day.

$ In the Peg-IFN α-2b arm: 40–65 kg of weight: 800 mg/day; >65-85 kg: 1,000 mg/day; >85-105 kg: 1,200 mg/day; >105-125 kg: 1,400 mg/day. In the Peg-IFN α-2a arm: <75 kg: 1,000 mg/day; ≥75 kg: 1,200 mg/day.

^ In the Peg-IFN α-2a arm: <75 kg of weight: 1,000 mg/day; ≥75 kg: 1,200 mg/day. In the Peg-IFN α-2b arm: <65 kg: 800 mg/day; 65–85 kg: 1,000 mg; >85 kg: 1,200 mg.

ç <75 kg of weight: 1,000 mg/day; ≥75 kg: 1,200 mg/day.

Coppola et al.

Coppola et al. BMC Infectious Diseases 2012 12:357   doi:10.1186/1471-2334-12-357

Open Data